Jeffrey Rubnitz, MD, PhD

A new look at an old drug: Improving AML survival

The quest to improve cure rates for children with acute myeloid leukemia (AML) got a boost recently from a study led by St. Jude Children’s Research Hospital. The research, published in the journal Cancer, took a new look at an old drug.

The drug, trade named Mylotarg, was withdrawn from the market in 2010 due to concerns about its safety and effectiveness. But scientists found that the drug likely helped children with high-risk AML who received the medication while it was on the market.

Mylotarg targets AML cells that carry a certain protein on their surface. St. Jude investigators are working to develop new treatments that target the same protein. The research may provide desperately needed new agents to help AML patients whose cancer returns or persists.

November 15, 2013

Read the news release